William Blair Analysts Increase Earnings Estimates for TWST

Twist Bioscience Co. (NASDAQ:TWST) – William Blair increased their Q2 2025 earnings estimates for shares of Twist Bioscience in a report released on Tuesday, February 4th. William Blair analyst M. Larew now anticipates that the company will post earnings of ($0.55) per share for the quarter, up from their previous estimate of ($0.57). The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.27) per share. William Blair also issued estimates for Twist Bioscience’s Q3 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.07) EPS, Q1 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.28) EPS and FY2026 earnings at ($1.49) EPS.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The business had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same quarter in the previous year, the business earned ($0.75) earnings per share. The business’s revenue for the quarter was up 24.1% on a year-over-year basis.

Several other equities analysts have also commented on TWST. Robert W. Baird increased their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday. TD Cowen reaffirmed a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Barclays lowered their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. JPMorgan Chase & Co. upped their price target on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research note on Tuesday. Finally, Leerink Partners lifted their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $53.80.

Twist Bioscience Stock Up 3.2 %

NASDAQ TWST opened at $53.66 on Thursday. The company has a 50-day moving average of $48.74 and a 200-day moving average of $46.27. Twist Bioscience has a 12 month low of $27.41 and a 12 month high of $60.90.

Insider Activity at Twist Bioscience

In related news, COO Patrick John Finn sold 10,340 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $496,320.00. Following the completion of the transaction, the chief operating officer now owns 221,061 shares of the company’s stock, valued at approximately $10,610,928. This represents a 4.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Dennis Cho sold 1,507 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $72,336.00. Following the sale, the insider now owns 91,163 shares of the company’s stock, valued at approximately $4,375,824. This trade represents a 1.63 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 59,002 shares of company stock worth $2,851,681. 3.01% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience in the third quarter worth $34,000. Van ECK Associates Corp grew its holdings in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after acquiring an additional 267 shares in the last quarter. Signaturefd LLC increased its position in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the last quarter. US Bancorp DE raised its stake in shares of Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after purchasing an additional 601 shares in the last quarter. Finally, Beaird Harris Wealth Management LLC bought a new position in shares of Twist Bioscience during the third quarter worth about $95,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.